United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

Posted by Geri Gentry on Jun 11th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $545.83, for a total transaction of $5,185,385.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at $22,113,210.79. The trade was a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

United Therapeutics Price Performance

NASDAQ UTHR traded up $1.30 during mid-day trading on Thursday, hitting $545.40. The company’s stock had a trading volume of 395,406 shares, compared to its average volume of 479,446. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The stock’s fifty day simple moving average is $568.19 and its two-hundred day simple moving average is $520.67. The firm has a market capitalization of $23.15 billion, a P/E ratio of 20.13, a price-to-earnings-growth ratio of 1.80 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the previous year, the business posted $6.63 EPS. The company’s quarterly revenue was down 1.6% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on UTHR shares. UBS Group lifted their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Cantor Fitzgerald lifted their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Bank of America lifted their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Finally, Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

Check Out Our Latest Research Report on UTHR

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of UTHR. Torren Management LLC acquired a new position in shares of United Therapeutics in the fourth quarter worth about $26,000. Activest Wealth Management raised its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC raised its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its position in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new position in United Therapeutics during the fourth quarter valued at approximately $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.